Skip to main content
×
Home
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 12, Issue 4
  • May 2009, pp. 459-473

What predicts attrition in second step medication treatments for depression?: a STAR*D Report

  • Diane Warden (a1), A. John Rush (a1) (a2), Stephen R. Wisniewski (a3), Ira M. Lesser (a4), Susan G. Kornstein (a5), G. K. Balasubramani (a3), Michael E. Thase (a6), Sheldon H. Preskorn (a7), Andrew A. Nierenberg (a8), Elizabeth A. Young (a9), Kathy Shores-Wilson (a1) and Madhukar H. Trivedi (a1)
  • DOI: http://dx.doi.org/10.1017/S1461145708009073
  • Published online: 09 July 2008
Abstract
Abstract

Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out are less likely to reach remission. This report evaluates the incidence, timing, and predictors of attrition during second-step medication treatment. Outpatients in the multisite Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study receiving a medication augmentation (n=563) or medication switch (n=723) for non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated to determine attrition rates and pretreatment sociodemographic or clinical predictors of attrition. Twenty percent of participants receiving a medication augmentation and 27% receiving a medication switch dropped out before 12 wk in the second treatment step. Remission rates were lower for dropouts [7% vs. 43% (medication augmentation); 12% vs. 31% (medication switch)]. For medication augmentation, Black and other non-Caucasian races, Hispanic ethnicity, younger age, family history of drug abuse, concurrent drug abuse, sociodemographic disadvantage, less symptom improvement with initial citalopram treatment, and greater symptom severity when beginning augmentation were associated with attrition. For medication switch, Black and other non-Caucasian races, younger age, more melancholic features, and lower exit doses but more severe side-effects with citalopram treatment were associated with attrition. Minority status, younger age, and greater difficulty with the first treatment step are risk factors for attrition in the second treatment step. Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes.

Copyright
Corresponding author
Address for correspondence: D. Warden, Ph.D., M.B.A., Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9119. Tel.: +1-214-648-4614Fax: +1-214-648-0168E-mail: Diane.Warden@UTSouthwestern.edu
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

BA Arnow , C Blasey , R Manber , MJ Constantino , JC Markowitz , DN Klein , ME Thase , JH Kocsis , AJ Rush (2007). Dropouts versus completers among chronically depressed outpatients. Journal of Affective Disorders 97, 197202.

LA Cooper , JJ Gonzales , JJ Gallo , KM Rost , LS Meredith , LV Rubenstein , NY Wang , DE Ford (2003). The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Medical Care 41, 479489.

K Demyttenaere , E Van Ganse , J Gregoire , E Gaens , P Mesters (1998). Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. International Clinical Psychopharmacology 13, 1117.

M Dwight-Johnson , CD Sherbourne , D Liao , KB Wells (2000). Treatment preferences among depressed primary care patients. Journal of General Internal Medicine 15, 527534.

M Fava , AJ Rush , MH Trivedi , AA Nierenberg , ME Thase , HA Sackeim , FM Quitkin , S Wisniewski , PW Lavori , JF Rosenbaum , DJ Kupfer (2003). Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatric Clinics of North America 26, 457494.

M Hamilton (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 5662.

M Hamilton (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278296.

RM Hirschfeld , DL Dunner , G Keitner , DN Klein , LM Koran , SG Kornstein , JC Markowitz , I Miller , CB Nemeroff , PT Ninan , (2002). Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry 51, 123133.

AY Khan , J Carrithers , SH Preskorn , R Lear , SR Wisniewski , AJ Rush , D Stegman , C Kelley , K Kreiner , AA Nierenberg , M Fava (2006). Clinical and demographic factors associated with DSM-IV melancholic depression. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists 18, 9198.

BS Linn , MW Linn , L Gurel (1968). Cumulative illness rating scale. Journal of the American Geriatrics Society 16, 622626.

CA Melfi , AJ Chawla , TW Croghan , MP Hanna , S Kennedy , K Sredl (1998). The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Archives of General Psychiatry 55, 11281132.

MD Miller , CF Paradis , PR Houck , S Mazumdar , JA Stack , AH Rifai , B Mulsant , III CF Reynolds (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Research 41, 237248.

JC Mundt , IM Marks , MK Shear , JH Greist (2002). The Work and Social Adjustment Scale: a simple measure of impairment in functioning. British Journal of Psychiatry 180, 461464.

JS Novick , JW Stewart , SR Wisniewski , IA Cook , R Manev , AA Nierenberg , JF Rosenbaum , K Shores-Wilson , GK Balasubramani , MM Biggs , S Zisook , AJ Rush (2005). Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D. Journal of Clinical Psychiatry 66, 10021011.

AJ Rush , IH Bernstein , MH Trivedi , TJ Carmody , S Wisniewski , JC Mundt , K Shores-Wilson , MM Biggs , A Woo , AA Nierenberg , M Fava (2006a). An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biological Psychiatry 59, 493501.

AJ Rush , TJ Carmody , PE Reimitz (2000). The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research 9, 4559.

AJ Rush , M Fava , SR Wisniewski , PW Lavori , MH Trivedi , HA Sackeim , ME Thase , AA Nierenberg , FM Quitkin , TM Kashner , (2004). Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Controlled Clinical Trials 25, 119142.

AJ Rush , HC Kraemer , HA Sackeim , M Fava , MH Trivedi , E Frank , PT Ninan , ME Thase , AJ Gelenberg , DJ Kupfer , (2006b). Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 31, 18411853.

AJ Rush , MH Trivedi , HM Ibrahim , TJ Carmody , B Arnow , DN Klein , JC Markowitz , PT Ninan , S Kornstein , R Manber , (2003). The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573583 [Erratum, p. 585].

AJ Rush , MH Trivedi , SR Wisniewski , JW Stewart , AA Nierenberg , ME Thase , L Ritz , MM Biggs , D Warden , JF Luther , (2006c). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New England Journal of Medicine 354, 12311242.

AJ Rush , M Zimmerman , SR Wisniewski , M Fava , SD Hollon , D Warden , MM Biggs , K Shores-Wilson , RC Shelton , JF Luther , (2005). Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. Journal of Affective Disorders 87, 4355.

JR Tedlow , M Fava , LA Uebelacker , JE Alpert , AA Nierenberg , JF Rosenbaum (1996). Are study dropouts different from completers? Biological Psychiatry 40, 668670.

MH Trivedi , M Fava , SR Wisniewski , ME Thase , F Quitkin , D Warden , L Ritz , AA Nierenberg , BD Lebowitz , MM Biggs , (2006a). Medication augmentation after the failure of SSRIs for depression. New England Journal of Medicine 354, 12431252.

MH Trivedi , AJ Rush , BN Gaynes , JW Stewart , SR Wisniewski , D Warden , L Ritz , JF Luther , D Stegman , J DeVeaugh-Geiss , R Howland (2007). Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 32, 24792489.

MH Trivedi , AJ Rush , HM Ibrahim , TJ Carmody , MM Biggs , T Suppes , ML Crismon , K Shores-Wilson , MG Toprac , EB Dennehy , (2004). The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine 34, 7382.

MH Trivedi , AJ Rush , SR Wisniewski , AA Nierenberg , D Warden , L Ritz , G Norquist , RH Howland , B Lebowitz , PJ McGrath , (2006b). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 2840.

D Warden , MH Trivedi , SR Wisniewski , L Davis , AA Nierenberg , BN Gaynes , S Zisook , SD Hollon , GK Balasubramani , R Howland , (2007). Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. American Journal of Psychiatry 164, 11891197.

JE Ware , M Kosinski , SD Keller (1996). A 12-item Short-Form Health Survey. Construction of scales and preliminary tests of reliability and validity. Medical Care 34, 220233.

SR Wisniewski , H Eng , L Meloro , R Gatt , L Ritz , D Stegman , M Trivedi , MM Biggs , E Friedman , K Shores-Wilson , (2004). Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clinical Trials (London, England) 1, 387398.

SR Wisniewski , M Fava , MH Trivedi , ME Thase , D Warden , G Niederehe , ES Friedman , MM Biggs , HA Sackeim , K Shores-Wilson , (2007). Acceptability of second-step treatments to depressed outpatients: a STAR*D report. American Journal of Psychiatry 164, 753760.

SR Wisniewski , AJ Rush , GK Balasubramani , MH Trivedi , AA Nierenberg (2006). Self-rated global measure of the frequency, intensity, and burden of side effects. Journal of Psychiatric Practice 12, 7179.

M Zimmerman , JI Mattia (2001a). A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Archives of General Psychiatry 58, 787794.

M Zimmerman , JI Mattia (2001b). The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Comprehensive Psychiatry 42, 175189.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: